A Randomized, 6-week, Double-blind, Placebo-controlled, Fixed-dose, Parallel Group Study of Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features
Phase of Trial: Phase III
Latest Information Update: 10 Nov 2015
At a glance
- Drugs Lurasidone (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Acronyms RESOLVE-2
- 10 Nov 2015 Primary endpoint has been met. (Montgomery-Asberg Depression Rating Scale)
- 10 Nov 2015 Results published online in the American Journal of Psychiatry.
- 10 Nov 2015 Status changed from withdrawn prior to enrolment to completed, as reported in the American Journal of Psychiatry.